Abivax S.A. American Depositary Receipt (ABVX)
NASDAQ (NMS) NASDAQ (NMS) Primary 
XSTU Summary
Abivax SA Sponsored ADR (ABVX) Upgraded to Buy: Here's What You Should Know
Abivax SA Sponsored ADR (ABVX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Are Medical Stocks Lagging Abivax SA Sponsored ADR (ABVX) This Year?
Here is how Abivax SA Sponsored ADR (ABVX) and Catalyst Pharmaceutical (CPRX) have performed compared to their sector so far this year.
Abivax: Betting Big On The Next Inflammatory Bowel Disease Blockbuster
ABIVAX Société Anonyme [NASDAQ: ABVX] is rated a Strong Buy with a $105 price target, driven by Obefazimod's best-in-class potential for ulcerative colitis (UC). ABVX's Obefazimod shows robust efficacy and differentiation in early Phase 3 trials, targeting a large, fast-growing inflammatory bowel disease market. Upcoming Phase 3 maintenance data in Q2 2026 is a major catalyst, with positive results likely to unlock significant upside for ABVX shares.
Abivax S.A. American Depositary Receipt (ABVX) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
When is the next earnings date?
Has Abivax S.A. American Depositary Receipt ever had a stock split?
Abivax S.A. American Depositary Receipt Profile
| Biotechnology Industry | Healthcare Sector | Marc M. P. de Garidel CEO | NASDAQ (NMS) Exchange | 00370M103 CUSIP |
| FR Country | 69 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
ABIVAX Société Anonyme operates in the forefront of biotechnology with a focus on discovering and developing therapeutic solutions aimed at modulating the body's natural immune response. Founded in 2013 and with its headquarters in Paris, France, this clinical-stage company is dedicated to addressing chronic inflammatory diseases through innovative treatments. By leveraging the body's own regulatory mechanisms, ABIVAX aims to provide effective and potentially pioneering therapies for diseases that currently have limited treatment options.
Products and Services
- Obefazimod:
As the lead drug candidate of ABIVAX, obefazimod represents a significant advancement in the treatment of chronic inflammatory diseases. Currently, it is undergoing Phase 3 clinical trials for its efficacy against moderately to severely active ulcerative colitis in adults. This therapeutic approach underscores ABIVAX’s commitment to tackling unmet medical needs within the realm of inflammatory diseases through the utilization of the body's inherent mechanisms for restoring immune balance.
Contact Information
